Skip to main content
. 2021 Sep 23;26(12):1006–e2129. doi: 10.1002/onco.13949
Number of Patients, Male 35
Number of Patients, Female 0
Age Median: 71 years
Number of Prior Systemic Therapies None
Performance Status: ECOG

0 — 17

1 — 18

2 — 0

3 — 0

Unknown — 0

Other Prior therapies: nine of the patients in the enzalutamide‐only arm had prior progression on abiraterone; three of the patients in the enzalutamide‐only arm had prior progression on docetaxel.